Are F2-isoprostanes biomarkers of lipid peroxidation and does oxidized LDL contribute to atherosclerosis?

F2-isoprostanes and oxidized LDL (oxLDL) describe related but distinct aspects of oxidative vascular biology: the former measures lipid oxidative damage, whereas the latter can actively amplify arterial inflammation and plaque development.

Biomarker and clinical interpretation

• F2-isoprostanes are well-validated biomarkers of in-vivo lipid peroxidation. They are chemically stable products of nonenzymatic, free-radical oxidation of arachidonic acid, independent of cyclooxygenase. They reflect oxidative lipid injury but are not disease-specific and do not identify its source.
• Measurement quality is central: LC–MS/MS or GC–MS with isotope-labeled internal standards provides the most specific results. Urinary measurement is practical and less prone than plasma to ex-vivo autoxidation; spot urine is often creatinine-normalized, though creatinine itself varies with renal function, muscle mass, and diet.
• No universal cutoff applies across assays, matrices, or populations. A normal value does not exclude intermittent or localized oxidative injury.

Vascular mechanisms

• oxLDL activates endothelial LOX-1, oxidative-stress pathways, and NF-κB, increasing VCAM-1, ICAM-1, selectins, and chemokines including MCP-1/CCL2. These changes facilitate leukocyte rolling, adhesion, and transmigration into the arterial wall.
• Macrophage uptake of oxLDL through scavenger receptors such as CD36 and SR-AI/II is not constrained by normal LDL-receptor feedback, promoting lipid accumulation and foam-cell formation. CD36/TLR4–TLR6 signaling can further sustain inflammatory cytokine and chemokine production.

Plaque relevance

• These convergent processes support oxLDL as an active participant in plaque growth and necrotic-core development. Prospectively, higher circulating oxLDL was associated with carotid plaque progression (adjusted relative risk 1.23, highest versus lowest tertile), although this association alone cannot establish human causality.

Bottom line

• The claim is supported: F2-isoprostanes are robust lipid-peroxidation biomarkers, and oxLDL mechanistically contributes to endothelial activation, inflammatory-cell recruitment, and atherosclerosis. oxLDL testing, however, is not established for routine cardiovascular risk assessment or treatment decisions.